2. Overview of secondary malignant neoplasm (SMN) cases and their primary tumours in the dexrazoxane and control groups.
| Dexrazoxane group | Control group | ||||
| Primary tumour | SMN | Primary tumour | SMN | ||
| 1 | HL | MDS | 1 | HL | AML |
| 2 | HL | Papillary carcinoma | 2 | HL | AML |
| 3 | HL | AML | 3 | ALL | Melanoma |
| 4 | HL | AML | 4 | L‐NHL | Myeloid sarcoma |
| 5 | HL | AML | 5 | T‐ALL + CNS | AML |
| 6 | HL | AML | 6 | T‐ALL | DLBL |
| 7 | HL | AML | |||
| 8 | HL | Osteosarcoma | |||
| 9 | T‐ALL | AML | |||
| 10 | T‐ALL | AML | |||
| 11 | L‐NHL | Astrocytoma | |||
| 12 | L‐NHL | Astrocytoma | |||
| 13 | T‐ALL | Glioblastoma multiforme | |||
| 14 | T‐ALL + CNS | Glioblastoma multiforme | |||
| 15 | T‐ALL | Medulloblastoma | |||
| 16 | L‐NHL | Papillary carcinoma ‐ thyroid | |||
P9426: numbers 1 to 5 of the dexrazoxane group and number 1 of the control group P9425: numbers 6 to 8 of the dexrazoxane group and number 2 of the control group DFCI 95‐01: number 3 of the control group P9404: numbers 9 to 16 of the dexrazoxane group and 4 to 6 of the control group
ALL: acute lymphoblastic leukaemia AML: acute myeloid leukaemia CNS: central nervous system DLBL: diffuse large B‐cell lymphoma DOX: doxorubicin ETOP: etoposide HDM: high‐dose methotrexate HL= Hodgkin lymphoma L‐NHL: lymphoblastic non‐Hodgkin lymphoma MDS: myelodysplastic syndrome RT: radiotherapy SMN: secondary malignant neoplasm T‐ALL: T‐cell acute lymphoblastic leukaemia